Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year ...
Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual ...
1mon
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for people to stay awake.
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results